Blood marker may reveal bone lesions in myeloma patients
NCT ID NCT02800954
First seen Nov 19, 2025 · Last updated Jun 23, 2026 · Updated 38 times
Summary
This study looked at whether a substance called M-CSF in the blood can indicate bone damage in people with multiple myeloma. Researchers compared M-CSF levels in 111 participants: those with multiple myeloma, those with a pre-cancer condition called MGUS, and healthy controls. The goal was to see if M-CSF could be a new marker for bone lesions, which are common and serious in myeloma.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CH Beauvais
Beauvais, 60021, France
-
CHU Amiens
Amiens, 80054, France
-
Ch Saint Quentin
Saint-Quentin, 02321, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could lead to a simple blood test to detect bone damage in multiple myeloma patients earlier.
What could go wrong
This is an observational study, not a treatment trial. It is small and may not confirm M-CSF as a reliable marker.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.